Joint U.S. Commercialization of RedHill's Talicia® Commences [Accessibility Statement] Skip NavigationThe full sales and operational launch of Talicia, under the joint commercialization agreement between Talicia Holdings Inc. (THI), a jointly controlled entity of RedHill and Cumberland has started and is now being rolled out to support accelerated market penetration and expanded reachFocused on unlocking the full market potential of Talicia, the #1 branded U.S. gastroenterologist-prescribed H. pylori therap ...

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE 2025 ANNUAL FINANCIAL RESULTS & COMPANY UPDATE [Accessibility Statement] Skip NavigationNASHVILLE, Tenn., Feb. 24, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its 2025 financial results and provide a company update after the market closes on Tuesday, March 3, 2026.A conference call will be held on March 3 at 4:30 p.m. Eastern Time to discuss the results and update.The link ...

Israel 2834 Not Applicable (Primary Standard Industrial Classification Code Number) As filed with the Securities and Exchange Commission on January 22, 2026 Registration No. 333-292528 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 REDHILL BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant's name into English) (State or other jurisdiction o ...

Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 As filed with the Securities and Exchange Commission on December 31, 2025 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 REDHILL BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant's name into English) (Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices) RedHill Biopharma In ...

Core Points - The New York Supreme Court awarded RedHill approximately $1.82 million in legal costs and expenses, in addition to a prior summary judgment of approximately $8.25 million in favor of RedHill against Kukbo Co. Ltd [1][2] - Both awards include a 9% ongoing statutory interest accrual [2] - RedHill successfully obtained an attachment grant from Korea's Incheon District Court against Kukbo, allowing for the seizure of Kukbo's assets [2] Company Overview - RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of drugs for gastrointestinal diseases, infectious diseases, and oncology [4] - The company promotes the FDA-approved gastrointestinal drug Talicia® for treating Helicobacter pylori infection in adults [4] - Key clinical late-stage development programs include: - Opaganib (ABC294640), targeting multiple indications including COVID-19 and prostate cancer [4] - RHB-204, aimed at Crohn's disease and pulmonary nontuberculous mycobacteria [4] - RHB-107 (upamostat), in late-stage development for non-hospitalized symptomatic COVID-19 and other diseases [4] - RHB-102, with potential applications for chemotherapy-induced nausea and vomiting [4]

Core Insights - The article discusses the initiation of a Phase 2 study evaluating the combination of opaganib and darolutamide in patients with advanced prostate cancer, sponsored by ANZUP and supported by Bayer and Ramsay Hospital Research Foundation [1][2] - Prostate cancer is a significant global health issue, with approximately 1.5 million new cases and nearly 400,000 deaths annually, representing a market worth around $12 billion [1][5] Study Overview - The Phase 2 study will involve 60 participants and is designed to assess the efficacy of opaganib in overcoming resistance to standard androgen receptor pathway inhibitors [2][3] - The study will utilize the PCPro lipid biomarker test to identify patients with poor prognosis who may benefit from the treatment combination [3][5] - The primary endpoint of the study is to improve 12-month radiographic progression-free survival (rPFS), with several secondary and exploratory endpoints also being evaluated [3] Prostate Cancer Context - Prostate cancer is the second most diagnosed cancer globally, with a significant increase in cases, nearly 120% from 1990 to 2019 [6] - The survival rates for prostate cancer vary significantly by stage, with a 100% five-year survival rate for Stage 1, dropping to 28% for Stage 4 [7] Androgen Receptor Pathway Inhibitors (ARPI) - ARPI is a key therapeutic strategy for treating castration-resistant prostate cancer, targeting male hormones that promote cancer cell growth [8] - Darolutamide is one of the key therapeutic options in this category, alongside enzalutamide and apalutamide [8] Opaganib Profile - Opaganib is an investigational drug with anticancer, anti-inflammatory, and antiviral properties, targeting multiple indications including various cancers [9][10] - The drug works by inhibiting multiple pathways and has shown potential in enhancing the efficacy of androgen receptor signaling inhibitors [4][10] Company Background - RedHill Biopharma is focused on developing and commercializing drugs for gastrointestinal diseases, infectious diseases, and oncology, with opaganib being a key part of its late-stage development programs [18]

Core Points - RedHill Biopharma Ltd. has secured a court ruling in its favor against Kukbo Co. Ltd., with a summary judgment amounting to approximately $8.25 million plus legal fees and costs [1][3] - The New York Supreme Court dismissed all counterclaims made by Kukbo, reinforcing RedHill's position in the legal dispute [1] - An attachment petition in South Korea has been granted, preventing Kukbo from disposing of its assets prior to enforcement of the judgment [1][2] Financial Implications - The summary judgment includes approximately $1.75 million in accrued interest at a rate of 9%, due to Kukbo's failure to adhere to the terms of subscription and licensing agreements [3] - Legal fees and costs are also recoverable as per the court's ruling, indicating potential additional financial recovery for RedHill [3] Legal Context - Kukbo has filed a notice of appeal against the judgment, with a six-month window to perfect its appeal, which may be extended [4] - The outcome of the appeal process could impact the enforcement of the judgment and the collection of the awarded amount [4] Company Overview - RedHill Biopharma is focused on the development and commercialization of drugs for gastrointestinal diseases, infectious diseases, and oncology [5] - The company promotes the FDA-approved drug Talicia® for treating H. pylori infection and has several late-stage clinical development programs targeting various diseases [5]